OS Cancer Research Results
OS, overall survival: Click to Expand ⟱
| Source: |
| Type: |
Overall survival
|
Scientific Papers found: Click to Expand⟱
PKM2↓, Treatment with 2-DG had no obvious effects on the total level of pyruvate kinase M2 (PKM2), but it significantly suppressed LPS-induced elevation of PKM2 in the nuclei.
Inflam↓, provided anti-inflammatory benefits in lethal inflammation.
TNF-α↓, LPS-induced elevation of pulmonary TNF-α (Figure 2C) and IL-6 (Figure 2D) were also suppressed by 2-DG.
IL6↓,
OS↑, Posttreatment with 2-DG Improved the Survival of LPS-Insulted Mice
Glycolysis↓, 3BP targets cancer cells’ energy metabolism, both its high glycolysis (“Warburg Effect”) and mitochondrial oxidative phosphorylation.
mt-OXPHOS↓,
ATP↓, This inhibits/ blocks total energy production leading to a depletion of energy reserves. Moreover, 3BP as an “Energy Blocker”, is very rapid in killing such cells.
selectivity↑, 3BP at its effective concentrations that kill cancer cells has little or no effect on normal cells.
toxicity↝, The results obtained hold promise for 3BP as a future cancer therapeutic without apparent cyto-toxicity when formulated properly.
OS↑, The patient (Fig. 5) was able to survive a much longer period than expected with an improved quality of life, which is clearly attributable to the treatment with 3BP.
QoL↑,
| - |
in-vitro, |
CRC, |
HCT116 |
|
|
|
- |
in-vitro, |
CRC, |
Caco-2 |
|
|
|
- |
in-vitro, |
CRC, |
SW48 |
|
|
|
ATP↓, 3-Bromopyruvate (3BP) is a pyruvate analogue with alkylating properties that depletes cellular ATP levels and induces rapid cell death in neoplastic cells with limited cytotoxic effects against normal cells.
TumCD↑,
selectivity↑,
toxicity↓, 3BP treatment led to eradication of tumours of hepatocellular carcinoma cell origin in rats without apparent cytotoxic effects [19]
OS↑, first human case report suggested that 3BP was able to prolong survival in a cancer patient diagnosed with hepatocellular carcinoma in 2012 [19,20].
HK2?, 3BP is able to dissociate and inhibit mitochondrial HKII function, thereby reducing ATP production. 3BP binding also frees up binding sites previously occupied by HKII
Cyt‑c↑, llowing pro-apoptotic molecules (such as BAX and BAD) to promote the release of cytochrome c into the cytosol and induce eventual cell death
eff↑, Raji lymphoma cells grown under hypoxic conditions were more sensitive to 3BP than in normoxia
p‑Akt↑, 3BP induces rapid AKT phosphorylation at residue Thr-308
toxicity↑, German police took action on 4 August after two patients from the Netherlands and one from Belgium died shortly after undergoing treatment at the Biological Cancer Centre, run by alternative practitioner Klaus Ross in the town of Brüggen, Germany
Glycolysis↓, It is believed to "starve" tumor cells to death by inhibiting glycolysis, the breakdown of glucose molecules to provide cells with energy.
eff↑, experiments on human cancer cell lines showed that combining another chemotherapeutic with 3BP increased its efficacy.
OS↑, the patient "was able to survive a much longer period than expected with an improved quality of life, which is clearly attributable to the treatment with 3BP,
QoL↑,
toxicity↝, Vogl says doctors should "absolutely" not perform systemic infusions, in which the drug circulates through the entire body. "
TrxR↓, AF treatment decreased TrxR activity and clonogenic survival in small cell lung cancer (SCLC) cell lines (DMS273 and DMS53) as well as the lung atypical (neuroendocrine tumor) NET cell line H727.
eff↑, AF treatment also significantly sensitized DMS273 and H727 cell lines in vitro to sorafenib, a multi-kinase inhibitor that was shown to decrease intracellular glutathione.
Dose↝, AF was administered intraperitoneally at 2 mg/kg or 4 mg/kg (IP) once (QD) or twice daily (BID) for 1 to 5 days in mice with DMS273 xenografts.
OS↑, When this daily AF treatment was extended for 14 days a significant prolongation of median survival from 19 to 23 days (p=0.04, N=30 controls, 28 AF) was observed without causing changes in animal bodyweight, CBCs, bone marrow toxicity, blood urea ni
eff↑, We also demonstrated that suppressing TrxR with AF can sensitize breast cancer stem cells to ROS induced stem cell transitions associated with EMT and cytotoxicity associated with 2-deoxyglucose treatment.
ChemoSen↑, AGI significantly enhanced the sensitivity of cancers to chemo-drugs with pooled RRs (95% CI) of 1.25 (1.18, 1.32), prolonged the 1-year survival rate of patients
OS↑,
| - |
in-vitro, |
BC, |
BT549 |
|
|
|
- |
in-vitro, |
BC, |
MDA-MB-231 |
|
|
|
- |
in-vitro, |
Nor, |
MCF10 |
|
|
|
TumCD↑, Our findings provide additional support for proteotoxic stress as a mechanism by which AgNPs selectively kill TNBCs
selectivity↑,
*toxicity↝, Failure to separate dissolved silver cations (Ag+) from AgNPs before toxicity testing likely contributes to the lack of a definitive answer. Ag+ is highly toxic and has a distinct cytotoxic mechanism of action compared to AgNPs;
Dose↝, doses in the range of 4–6 mg/kg delivered systemically for multiple weeks induced therapeutic responses
OS↑, 40 patients were injected intravenously with 1.8 mg of AgNPs for 3 consecutive days (combined with standard COVID-19 treatments), and the group receiving AgNPs had significantly greater survival rate
OS↑, Results indicate that the AgNPs were efficient in prolongation of life span, reduction of tumor volume and body weight in tumor animals.
TumVol↓,
Weight↑,
AntiTum↑, AgNPs are potent in antitumor activity and the molecular mechanism is by the induction of apoptosis through the mitochondrial dependent and independent pathways.
Apoptosis↑,
mtDam↑,
| - |
in-vitro, |
CRC, |
HCT116 |
|
|
|
- |
in-vitro, |
CRC, |
HT29 |
|
|
|
- |
in-vivo, |
NA, |
NA |
|
|
|
eff↑, large surface area-to-volume ratio, which can be exploited in cancer radiotherapy to locally enhance the radiation dose deposition in tumors
TumCG↓, Treatment with nanoparticles and a single radiation dose of 10 Gy significantly reduces the growth of colorectal tumors
OS↑, increases the survival time as compared to treatment with radiation only
RadioS↑, combine standard-dose radiotherapy with radiosensitizers to enhance the radiation therapy efficacy locally within tumors while sparing adjacent healthy tissues
eff↑, suggested that graphene enhances the cellular uptake when combined with metals in nanocomposites
ROS↑, ROS, the most potent of these free radicals, can travel to and indirectly damage DNA
DNAdam↑,
eff↝, PEGylated GQD-decorated Silver Nanoprisms (pGAgNPs) show better intracellular uptake as compared to PEGylated Silver Nanoprisms (pAgNPs)
OS↑,
OS↑,
OS↑, 500% improvement
OS↑, remission
Dose↓, Electron microscopy of AgNP solution revealed bimodal nanoparticle size
distribution: 3 and 12 nm.
BioAv↝, basal **silver ion** concentrations of 32 ng/g, rising to 46 ng/g 1 hour after ingesting 60 mL of AgNP solution.
toxicity↓, no toxicities were observed and he had complete radiographic resolution of his cancer
Remission↑,
other↝, patient serum was analyzed and intact nanoparticles were not identified. Thus, we could not isolate the circulating AgNP form
other↝, Analysis of urine showed no AgNP or detectable nanoparticle fragments
other↝, AgNP solution was also exposed to simulated gastric fluid, in which they aggregated into larger nanoparticles according to UV-Vis absorption.
Dose↝, GDH: based on repeat setup, estimated PPM is 20PPM assuming 67% effecient. 1.2mg/60mL (he took 160mL/day
BioAv↝, GDH: chatAI computed the estimated bioavailability at 7%
| - |
vitro+vivo, |
lymphoma, |
NA |
|
|
|
OS↑, up 50%
ascitic↓, down 65%
| - |
Case Report, |
Melanoma, |
NA |
|
|
|
eff↑, Combining first-line anti-PD1 therapy and oral FMT with healthy donor stool in this small cohort was safe and demonstrated an improvement in ORR, mPFS, and mOS, compared with randomized trials
OS↑, At the time of data censoring (January 21, 2025), eight patients were alive with the longest ongoing follow-up at 62.2 months. None were on active therapy and seven without disease progression.
eff↑, This group demonstrated significantly improved mPFS, suggesting that mild early-onset GI toxicity reflects successful microbiota engraftment and immune priming, ultimately correlating with enhanced ICI efficacy
PSA↓, one patient
OS↑,
| - |
vitro+vivo, |
Melanoma, |
B16-F10 |
|
|
|
TumCG↓,
OS↑,
OS↑, >9 years
Weight↑, up 30 lbs
TumVol↓, PET/CT scan
OS↑,
Weight↑, During treatment body-mass-index increased by 3,4 ± 1,4% under L-Carnitine and decreased (−1,5 ± 1,4%) in controls
QoL↑, Moreover, nutritional status (body cell mass, body fat) and quality-of-life parameters improved under L-Carnitine.
OS↑, There was a trend towards an increased overall survival in the L-Carnitine group (median 519 ± 50 d versus 399 ± 43 d, not significant) and towards a reduced hospital-stay (36 ± 4d versus 41 ± 9d,n.s.).
EGFR↓, Almonertinib (HS-10296) is an oral, potent, high selective third generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) for sensitizing mutations and EGFR T790M mutation.
OS↑, Almonertinib demonstrated progression-free survival benefit in EGFR T790M positive NSCLC patients
Dose↝, received almonertinib 110 mg orally once daily until disease progression.
BBB↑, Both almonertinib and bevacizumab are capable of crossing the blood–brain barrier with comparable central nervous system effectiveness.
Dose↝, present five cases to further evaluate the effectiveness and tolerability of almonertinib in combination with bevacizumab for patients with EGFRm NSCLC and LM.
eff↓, For the first time, we report that almonertinib plus bevacizumab can not only effectively improve the neurological symptoms caused by LM but also prolong the survival time of patients with limited and controllable side effects, which provided a novel
OS↑,
EGFR↓, Aumolertinib is a well-tolerated third-generation epidermal growth factor receptor tyrosine kinase inhibitor that could serve as a treatment option for EGFR-mutant NSCLC in the first-line setting.
eff↝, Objective response rate and disease control rate were similar in the aumolertinib and gefitinib groups (objective response rate, 73.8% and 72.1%, respectively;
OS↑, see figure 1
TumCD↑, curcumin has been shown to modulate immunoediting processes including resurrecting immune surveillance mechanisms to help eradicate cancer cells
TumCG↓, studies by Lee-Chang et al34 have shown that administration of resveratrol, a dietary polyphenol compound possessing antioxidant properties at low doses that are nontoxic to immune cells, inhibits lung metastasis of breast cancer tumor.
ROS⇅, Of importance, resveratrol can exert both antioxidant and pro-oxidant properties depending on its concentration and cell types used
eff↑, Wang et al36 have demonstrated that a combination of fish oil and selenium that possesses anti-inflammatory and antioxidant activities exerted synergistic effects in suppressing lung tumor growth mediated via decreasing the population of splenic Treg
RadioS↑, Several nutritional cancer chemopreventive compounds having antioxidant properties have been documented to potentiate radiation therapy–induced cytotoxic effects on cancer cells while reducing its toxicity on normal surrounding tissues.77-86
TumCG↓, soy isoflavone component genistein on prostate cancer demonstrated that both soy and genistein inhibited the growth of in vitro human PC-3 prostate cancer cells and in vivo orthotopic PC-3 tumors
OS↑, While a statistically significant improved survival rate either at 1 year or 5 years was associated with melatonin supplementation
toxicity∅, 9 RCTs reported no differences in the toxicities by antioxidants supplementation
toxicity↑, and 1 RCT with vitamin A reported increased toxicity.
ChemoSen∅, There was no evidence of significant decreases in the efficacy of chemotherapy with antioxidant supplementation.
OS↑, There were some indications of improvements in survival, tumour response and incidence of toxicity, but studies were underpowered.
chemoP↑,
chemoP↑, Our comprehensive data suggests that antioxidant has superior potential of ameliorating chemotherapeutic induced toxicity
ChemoSen↑, Antioxidant supplementation during chemotherapy also promises higher therapeutic efficiency and increased survival times in patients
OS↑,
Dose↑, On the contrary, many integrative practitioner converse uses of antioxidant supplements allowing patients to tolerate possibly higher effective doses of chemotherapy
Risk↓, Among antioxidant users, frequent use of vitamin C and vitamin E was associated with decreased risk of BC recurrence, vitamin E use was associated with decreased risk of all cause mortality
eff↓, but conversely, frequent use of combination carotenoids was associated with increased risk of death from breast cancer and all cause mortality
OS↑, Among the flavonoid-treated patients with resected colon cancer (n = 14), there was no cancer recurrence and one adenoma developed
Remission↓,
Dose∅, The flavonoid- treated patients took a daily dose of 2 tablets of the flavonoid mixture[24] containing 10 mg apigenin and 10 mg epigallocatechin-gallate per tablet.
TumCP↓, API suppresses 4T1 cells proliferation
TumCMig↓, API restraints 4T1 cells migration and invasion
TumCI↓,
Apoptosis↑, API triggers 4T1 apoptosis and modulates the expression levels of apoptotic-associated proteins in 4T1 cells
MMP↑, API triggers the depolarization of ΔΨm in 4T1 cells
ROS↑, API induces ROS generation
p‑PI3K↓, The results revealed a significant downregulation of p-PI3K/PI3K, p-AKT/AKT, and Nrf2 in 4T1 cells following API treatment
PI3K↓,
Akt↓,
NRF2↓,
AntiTum↑, API exhibits anti-tumor activity in mice
OS↑, results of animal survival experiments show that API can appropriately prolong the survival of mice with mammary gland tumors
*OS↑, The untreated Act5C-Aβ42 flies live for approximately 16 days, while the Act5C-Aβ42
treated with Ashwagandha showed improvement in their lifespan living up to 29 days
*BACE↓, shwagandha was also shown to down-regulate beta-secretase 1
(BACE1) a
antiOx↑, confirming antioxidant, anti-inflammatory
Inflam↓,
TumCP↓, Withania somnifera reduces tumor cell proliferation while increasing overall animal survival time.
OS↑,
RadioS↑, enhance the effectiveness of radiation therapy
radioP↑, while potentially mitigating undesirable side effects
chemoP↑, reduces the side effects of chemotherapeutic agents cyclophosphamide and paclitaxel without interfering with the tumor-reducing actions of the drugs.
Remission↑, Complete remission was achieved in all 77 patients in the ATRA–arsenic trioxide group who could be evaluated (100%) and in 75 of 79 patients in the ATRA–chemotherapy group (95%)
OS↑, Two-year event-free survival rates were 97% in the ATRA–arsenic trioxide group and 86% in the ATRA–chemotherapy group
toxicity↓, As compared with ATRA–chemotherapy, ATRA–arsenic trioxide was associated with less hematologic toxicity and fewer infections but with more hepatic toxicity.
eff↑, After a median follow-up of 36 months (range 1-75 months), the 2-year EFS was 98% and 84.9% in the ATRA-ATO and ATRA-CHT groups respectively
OS↑, the 2-year overall survival (OS) rate was 99.1% vs. 94.4% (P=0.01) for ATRA-ATO vs ATRA-CHT, respectively.
toxicity↓, SY-2101 was well tolerated. Most adverse events were of low grade.
OS↑, Acute promyelocytic leukemia (APL) has evolved from a highly fatal disease to the most curable form of acute myeloid leukemia using a chemotherapy-free regimen of arsenic trioxide (ATO) IV and oral all trans retinoic acid (ATRA) with cure rates >90%
OS↑, Statin use before diagnosis was associated with improved overall survival compared with no treatment (hazard ratio [HR], 0.85; 95% CI, 0.80 to 0.91) and specifically in patients with leukemia, lung, or renal cancers.
eff↑, This study suggests that the combination of statins with drugs that affect isoprenylation, such as bisphosphonates, improves survival in patients with cancer.
other↝, However, patients younger than age 65 years in the comparison of statin users versus nonusers had improved survival, whereas those older than age 65 years did not.
lipid-P↓, Statins exhibit “pleiotropic” properties that are independent of their lipid-lowering effects.
TumCG↓, preclinical evidence suggests that statins inhibit tumor growth and induce apoptosis in specific cancer cell types.
Apoptosis↑,
ChemoSen↑, statins show chemo-sensitizing effects by impairing Ras family GTPase signaling.
RAS↓,
HMG-CoA↓, Statins are potent, competitive inhibitors of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase (HMGCR).
HMGCR↓,
LDL↓, Statins reduce blood plasma cholesterol levels by decreasing de novo cholesterol biosynthesis and by inducing changes in low density lipoprotein (LDL) receptor expression [2].
toxicity↓, Due to the well-established safety profile of statins, such studies are less expensive than the development of novel drugs.
Risk↓, statin use in cancer patients was associated with reduced cancer-related mortality. The risk of cancer death was significantly lower in postmenopausal women
P21↑, Other proposed mechanisms leading to an increase of p21 levels include the release of promoter-associated histone deacetylase and inhibition of histone deacetylase
HDAC↓,
Bcl-2↓, Statins trigger the intrinsic apoptosis pathway and decrease Bcl-2 protein expression [[154], [155], [156]], increase Bax and BIM protein expression [[156], [157], [158], [159]], and activate several caspases
BAX↑,
BIM↑,
Casp↑,
cl‑PARP↑, thereby increasing cleaved PARP-1 levels.
MMP↓, different tumor cell lines (breast, brain, and lung) showed that simvastatin-induced apoptosis is dependent on decreasing mitochondrial membrane potential and increasing reactive oxygen species (ROS) production
ROS↑,
angioG↓, Statins inhibit angiogenesis and metastasis
TumMeta↓,
PTEN↑, n breast cancer xenografts, simvastatin prevented tumor growth by reducing Akt phosphorylation and BclXL transcription, while simultaneously increasing the transcription of pro-apoptotic/anti-proliferative PTEN
eff↑, In mice, the administration of a combination of celecoxib and atorvastatin was more effective than each individual treatment, and effectively prevented prostate cancer progression from androgen dependent to androgen independent
OS↑, Long-term statin use may improve survival in GBM patients treated with temozolomide chemotherapy
Remission↑, statin use during or after chemotherapy is not associated with improved disease-free-, recurrence-free-, or overall survival in stage II colon cancer patients
Apoptosis↑, The anti-tumor activity of statins is largely related to their ability to induce apoptosis by targeting cancer cells with high selectivity.
selectivity↑,
eff↑, Combining statins with histone deacetylase inhibitors can induce a synergistic anticancer effect.
HMG-CoA↓, 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, known as statins, are a commonly used and well-tolerated class of drugs used in lipid disorders,
*cardioP↑, Their effectiveness in preventing the development of cardiovascular diseases makes statins one of the most widely used drugs
OS↑, On the other hand, improved survival in patients with hepatocellular carcinoma, colon cancer or prostate cancer is visible after the use of any statin
IL1β↓, statins inhibit the synthesis of cytokines, including interleukin (IL-) IL-1β, IL-6, IL-8 and tumor necrosis factor alpha (TNF-α)
IL6↓,
IL8↓,
TNF-α↓,
TumAuto↑, Simvastatin-induced autophagy has been reported in rhabdomyosarcoma cells [
Histones↝, Statins are also involved in the regulation of the histone acetylation level.
ac‑H3↑, Studies indicate that statins increase histone H3 and H4 acetylation as well as inhibit class I and II HDACs
ac‑H4↑,
HDAC↓,
OS↑, The rate of objective response was 42% (5/12) and the disease control rate was 83% (10/12) in response to chemo-immunotherapy using lentinan, with a median overall survival of 407 days (95% CI: 207–700 days).
TNF-α↓, Beta-glucans suppress pro-inflammatory cytokines (e.g., TNF-α, IL-6) and tumor-promoting pathways like NF-κB, while modulating T-regulatory cells (Tregs) and downregulating PD-L1 to overcome immune evasion.
IL6↓,
NF-kB↓,
PD-L1↓,
Imm↑,
BAX↑, They induce apoptosis via Bax/Bcl-2 regulation, arrest cell cycles at G1/S or G2/M phases, and inhibit angiogenesis by targeting VEGF and MMPs.
Bcl-2↓,
TumCCA↑,
angioG↓,
VEGF↓,
MMPs↓,
OS↑, improved overall survival (OS) in melanoma (hazard ratio
chemoP↑, alongside reduced chemotherapy toxicity
eff↑, Synergy with PD-1/PD-L1 inhibitors enhances immunotherapy efficacy, particularly in immunogenic tumors.
BioAv↑, Advanced nano-delivery systems, including micelles and exosomes, improve bioavailability and tumor targeting.
Imm↑, One of the most well-studied trained immunity inducers, β-glucan, has been shown to reprogram HSPCs in the bone marrow,
ROS↑, Trained neutrophils induced by β-glucan exhibit enhanced degranulation and increased production of reactive oxygen species, enabling direct tumor cell killing (Kalafati et al., 2020).
Apoptosis↑, orally administered yeast-derived particulate β-glucan treatment reduces tumor burden and decreases the accumulation of PMN-MDSC, while simultaneously inducing oxidative burst and apoptosis in these cells
OS↑, In metastatic breast cancer models, trained immunity induced by particulate β-glucan has been shown to significantly prolong survival and reduce lung metastases
TumMeta↓,
Dose↝, Currently, i.p. injection of β-glucan is considered the gold standard in preclinical studies, as it induces robust trained immunity in mice.
Imm↑, The small β-glucans fragments are eventually released by the macrophages and taken up by other immune cells leading to various immune responses.
*BioAv↓, Repeated measurements of β-glucans in serum, however, revealed no systemic absorption of the agent following the oral administration. Nonetheless, the immunoglobulin A concentration in saliva increased significantly for the 400 mg/day arm, suggesting
OS↑, In a randomized trial, SPG combined with conventional chemotherapy improved the long term survival rate of patients with ovarian cancer [72].
ChemoSen↑, Maitake D-Fraction extracted from Grifola frondosa (Maitake mushroom) was found to decrease the size of the lung, liver and breast tumors in >60% of patients when it was combined with chemotherapy in a 2 arms control study comparing with chemotherapy
OS↑, Median overall survival was significantly longer in the former group than in the latter group [689 d (95% CI: 431-2339 d) vs 565 d (95% CI: 323-662 d), P = 0.0406].
eff↑, Our results showed that chemo-immunotherapy using lentinan was superior to chemotherapy alone in terms of survival
| - |
Review, |
Var, |
NA |
|
|
|
- |
Review, |
IBD, |
NA |
|
|
|
AntiTum↑, LNT are macromolecules with a β-1,3-D-glucan and its unique molecular structure is closely related to its pharmacological activity, and the glucan of the β-glycosidic bond is the key structure for its antitumor function [6, 7].
GutMicro↑, LNT could also improve the imbalance of gut microbial colonies [25].
*Inflam↓, LNT exerts its anti-inflammatory effect by downregulating cell surface TNFR1 to inhibit TNF-α-induced NF-κB activation
*TNF-α↓,
*NF-kB↓,
ChemoSen↑, LNT combined with cisplatin can not only reduce the dose of cisplatin, but also promote the activation of the intrinsic apoptosis pathway through the regulation of signals, leading to apoptosis of liver cancer cells
OS↑, LNT combined with pentafluorouracil improved survival time for advanced gastric cancer, which is consistent with the results of a meta-study of five randomized controlled trials [78, 79].
Imm↑, Although LNT has been approved in Japan as an immune agent for chemotherapy in gastric cancer
IL6↓, significantly enhance the immune function of CD4 cells, increase NK cells and reduce IL-6 levels
ERK↓, Studies have shown that LNT can inhibit the ERK/MAPK signaling pathway by regulating miR-340, thereby promoting apoptosis in osteosarcoma cells
MAPK↓,
*antiOx↑, LNT is an shiitake extract with anti-inflammatory, antioxidant, anti-tumor and other biological activities and functions.
eff↑, Furthermore,studies also found that LNT selenium nanoparticles can promote apoptosis by acting on specific signaling pathways [96, 97].
OS↑, Median survival was significantly longer in the lentinan group than in the control group (297 days vs. 199 days, p = 0.028).
QoL↑, Total QOL score, especially appetite and sleep quality, was significantly improved with the administration of lentinan.
PD-L1↓, lentinan treatment inhibited the platinum drug-stimulated expression of PD-L1 in gastric cancer cells mainly by suppressing MAPK signaling
MAPK↓,
OS↑, Lentinan has been reported to improve the overall survival of cancer patients receiving chemotherapy [23, 24] through its antitumor and immunomodulatory activitie
AntiTum↑,
Imm↑,
| - |
vitro+vivo, |
Lung, |
H460 |
|
|
|
- |
vitro+vivo, |
Lung, |
A549 |
|
|
|
TumCP↓, Baicalein significantly decreased lung cancer proliferation in H-460 cells in a dose dependent manner.
Apoptosis↑, dose-dependent induction in apoptosis associated with decreased cellular f-actin content, an increase in nuclear condensation and an increase in mitochondrial mass potential was observed.
F-actin↓,
TumVol↓, baicalein significantly (p < 0.05) reduced tumour growth and prolonged survival.
OS↑,
12LOX↓, demonstrated reduced expression of both 12-lipoxygenase and VEGF proteins in baicalein-treated tumours, relative to untreated.
VEGF↓,
angioG↓, improves survival in-vivo, an effect that is at least partly mediated through effects on cell cycle and tumour angiogenesis.
OS↑, BBR could sensitize ICB to inhibit tumor growth and increased the survival rate of mice.
ROS↑,
NQO1↓,
ICD↑,
OS↑, addition of atezolizumab to bevacizumab plus chemotherapy significantly improved overall and progression-free survival in patients with metastatic nonsquamous non-small cell lung cancer
eff↑, combining vascular normalization with immunotherapy may increase the efficacy of immunotherapy and reduce the risk of adverse reactions.
OS↑, The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer
GutMicro↑, Bifidobacterium, Escherichia, and Sarterella were significantly enriched in patients with clinical benefit response (p < 0.05), and these three bacteria had certain predictive value for clinical benefit.
OS↑, Patients with Bifidobacterium breve had significantly longer median progression‐free survival (mPFS) compared with patients with no detectable Bifidobacterium breve feces at baseline (106 days vs. NR, p < 0.001).
eff↑, The clinical efficacy of anti‐PD‐1 therapy combined with chemo in Chinese advanced NSCLC patients is closely related to the gut microbiota, and Bifidobacterium breve may be a potential biomarker to predict the efficacy of immune‐combined chemo
Imm↑, his review will focus on the immunomodulatory effects of Bifidobacteria in malignancies and the possible mechanisms of action of Bifidobacteria on immunotherapy
Risk↓, Bifidobacteria have a role in the prevention of intestinal cancer in healthy intestinal microbiota by influencing intestinal probiotics metabolism and enhancing the host immune response;
GutMicro↑,
AntiTum↑, Bifidobacteria has been shown to positively induce an anti-tumor immune response [32].
OS↑, Bifidobacterium longum 420 significantly increased the survival of mice carrying renal cell carcinoma tumors treated with anti-PD-1 and anti-CTLA-4 antibodies
selectivity↑, Bifidobacteria have been shown to selectively accumulate in tumors upon entry into the blood stream, possibly due to the hypoxic microenvironment’s
eff↑, (e.g., probiotic strains such as Bifidobacterium bifidum) to enhance the efficacy of cancer immunotherapy is still in its infancy,
Showing Research Papers: 1 to 50 of 247
Page 1 of 5
Next
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 247
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress ⓘ
antiOx↑, 1, ICD↑, 1, lipid-P↓, 1, NQO1↓, 1, NRF2↓, 1, mt-OXPHOS↓, 1, ROS↑, 5, ROS⇅, 1, TrxR↓, 1,
Mitochondria & Bioenergetics ⓘ
ATP↓, 2, MMP↓, 1, MMP↑, 1, mtDam↑, 1,
Core Metabolism/Glycolysis ⓘ
12LOX↓, 1, Glycolysis↓, 2, Histones↝, 1, HK2?, 1, HMG-CoA↓, 2, LDL↓, 1, PKM2↓, 1,
Cell Death ⓘ
Akt↓, 1, p‑Akt↑, 1, Apoptosis↑, 6, BAX↑, 2, Bcl-2↓, 2, BIM↑, 1, Casp↑, 1, Cyt‑c↑, 1, MAPK↓, 2, TumCD↑, 3,
Transcription & Epigenetics ⓘ
ac‑H3↑, 1, ac‑H4↑, 1, other↝, 4,
Autophagy & Lysosomes ⓘ
TumAuto↑, 1,
DNA Damage & Repair ⓘ
DNAdam↑, 1, cl‑PARP↑, 1,
Cell Cycle & Senescence ⓘ
P21↑, 1, TumCCA↑, 1,
Proliferation, Differentiation & Cell State ⓘ
ERK↓, 1, HDAC↓, 2, HMGCR↓, 1, PI3K↓, 1, p‑PI3K↓, 1, PTEN↑, 1, RAS↓, 1, TumCG↓, 5,
Migration ⓘ
F-actin↓, 1, MMPs↓, 1, TumCI↓, 1, TumCMig↓, 1, TumCP↓, 3, TumMeta↓, 2,
Angiogenesis & Vasculature ⓘ
angioG↓, 3, EGFR↓, 2, VEGF↓, 2,
Barriers & Transport ⓘ
BBB↑, 1,
Immune & Inflammatory Signaling ⓘ
IL1β↓, 1, IL6↓, 4, IL8↓, 1, Imm↑, 6, Inflam↓, 2, NF-kB↓, 1, PD-L1↓, 2, PSA↓, 1, TNF-α↓, 3,
Drug Metabolism & Resistance ⓘ
BioAv↑, 1, BioAv↝, 2, ChemoSen↑, 5, ChemoSen∅, 1, Dose↓, 1, Dose↑, 1, Dose↝, 6, Dose∅, 1, eff↓, 2, eff↑, 19, eff↝, 2, RadioS↑, 3, selectivity↑, 5,
Clinical Biomarkers ⓘ
ascitic↓, 1, EGFR↓, 2, GutMicro↑, 3, IL6↓, 4, PD-L1↓, 2, PSA↓, 1,
Functional Outcomes ⓘ
AntiTum↑, 5, chemoP↑, 4, OS↑, 49, QoL↑, 4, radioP↑, 1, Remission↓, 1, Remission↑, 3, Risk↓, 3, toxicity↓, 5, toxicity↑, 2, toxicity↝, 2, toxicity∅, 1, TumVol↓, 3, Weight↑, 3,
Total Targets: 98
Pathway results for Effect on Normal Cells:
Redox & Oxidative Stress ⓘ
antiOx↑, 1,
Immune & Inflammatory Signaling ⓘ
Inflam↓, 1, NF-kB↓, 1, TNF-α↓, 1,
Protein Aggregation ⓘ
BACE↓, 1,
Drug Metabolism & Resistance ⓘ
BioAv↓, 1,
Functional Outcomes ⓘ
cardioP↑, 1, OS↑, 1, toxicity↝, 1,
Total Targets: 9
Scientific Paper Hit Count for: OS, overall survival
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:229 State#:% Dir#:2
wNotes=on sortOrder:rid,rpid
Home Page